Are IL-2 smart cytokines the next big thing?
This issue of our newsletter is supported by Inpart.
IL-2 cytokine therapy was first approved for kidney cancer in 1992 to stop the spread of cancer cells in patients.
However, at that time, the safety of the therapy was quickly brought into question due to toxicities.
Now, though, there is a more advanced form of it being tested in the clinic.
These are called IL-2 smart cytokines - or superkines.
American biotech Mural Oncology is a leader in the space of superkines, as its drug nemvaleukin has received orphan drug and fast track designations from the FDA for the treatment of mucosal melanoma.
To find out more, read the full article: “Overcoming toxicities: are IL-2 smart cytokines the next big thing?”
A MESSAGE FROM OUR SPONSOR INPART
The Annual Partnering 2030 Survey is Open
Inpart is dedicated to helping make biopharma partnering more accessible and efficient. Our annual survey allows biotechs to communicate to pharma companies what matters most when it comes to partnering while highlighting key trends, challenges, and changes throughout the industry.
Share your insights and play your part in shaping the future of biopharma partnering.
🔥 More noteworthy articles from this week:
The average price of new drugs increased by 35% in the U.S. in 2023, reflecting in part the industry’s embrace of expensive gene therapies for rare diseases like muscular dystrophy. Here, we take a look at eight of the world’s most expensive drugs.
We observed World Malaria Day on April 25 and, as biotech makes progress in malaria research, we decided to take a look at some of the newest tools being developed to combat malaria, including vaccines, RNA-protein research, and nanotechnology.
The role of a research assistant entails a range of responsibilities that can vary depending on the setting. We spoke to Elina Kuznecova, a research assistant at the University of Oxford, to know more about what the role demands, and how integral research assistants are in supporting the biotech and life sciences industry.
As it is widely recognized that there is a significant need to make cell and gene therapies more affordable to patients, Brazil is now attempting to do just that, with a unique collaboration between U.S. non-profit organization Caring Cross and Fiocruz, the public health and research foundation funded by Brazil’s Ministry of Health.
There can be many challenges associated with starting clinical trials, including ensuring diversity, site selection, regulatory barriers, and patient retention. So, how can companies overcome clinical trial issues?
Laboratories still primarily rely on animal testing for quality control - but a recent guideline update encourages the biopharmaceutical industry to abandon the use of animals and move to new standards in biologics QC, including next-generation sequencing (NGS)-based assays.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.